Oncology Drugs– tag –
-
[Science News] Cancer Discovery Perspective: Restoring Tumor Suppressor Function of Mutant p53 via Small Molecules
A study published in the June 2025 issue of Cancer Discovery reports a novel small-molecule strategy to restore the tumor suppressor function of mutant p53 proteins. This work was also featured in a companion Perspective article, highlig... -
[Science News] Cancer Discovery Spotlight: CAFs Suppress NK Cells to Promote Breast Cancer Metastasis
A study published in the June 2025 issue of Cancer Discovery reveals how cancer-associated fibroblasts (CAFs) promote metastatic progression in breast cancer by suppressing natural killer (NK) cell cytotoxicity. This work was selected fo... -
[Science News] KRAS Inhibition and T-cell Dependency: Defining the Immune Role in Pancreatic Cancer Therapy (Cancer Discovery Summary / With My Thoughts)
A study published online in June 2025 in Cancer Discovery reveals that **T-cell–dependent tumor regression** is a key mechanism underlying the efficacy of KRAS G12D inhibitors in pancreatic ductal adenocarcinoma (PDAC). KRAS G12D is a ma... -
[Science News] Long-Term Latency of Highly Mutated Cells in Esophageal Squamous Cell Carcinoma: Cancer Discovery Summary (With My Thoughts)
A study published in the June 2025 issue of Cancer Discovery reveals that highly mutated cell clones carrying multiple driver mutations can persist for many years in esophageal squamous epithelium before progressing to esophageal squamou... -
Oncology Drug Approval News Flash: Tisotumab vedotin-tftv (Tivdak) Approved by FDA for Recurrent or Metastatic Cervical Cancer
[FDA Approval Alert] Tisotumab vedotin-tftv by Seagen and Genmab approved for recurrent/metastatic cervical cancer (June 21, 2025) On June 21, 2025, the U.S. FDA approved Tisotumab vedotin-tftv (Tivdak) for the treatment of recurrent or ...
1